Pfizer's API business revenue falls 13% on lower international sales

By Gareth Macdonald contact

- Last updated on GMT

Revenue generated by Pfizer’s API and contracting business fell in the second quarter.

The US drug firm’s contract manufacturing business – Pfizer CentreOne - generated $171m (€144m) in the three months to the end of June, down 13% on the year earlier quarter.

In the US, CentreOne – which is a unit of Pfizer’s Essential Health division - generated revenue of $132m, which is up $1m from the contribution in Q2 last year. In contrast, in international markets, the unit brought in $39m, down 39%.

The decline continues the trend seen in Q1 when the CentreOne unit’s revenue fell 8% to $182m as a result of lower international sales.

Pfizer’s total revenue for the second quarter was down 2% at $12.9bn.

Related news

Show more

Related product

TCC TB – a new filler for direct compression

TCC TB – a new filler for direct compression

Jungbunzlauer | 09-Oct-2017 | Technical / White Paper

TCC TB is a tricalcium citrate tetrahydrate designed to function as a direct compression excipient. It combines exceptional compression characteristics,...

Related suppliers